Humana Inc. (NYSE:HUM) is Welch Capital Partners LLC NY’s 5th Largest Position

Welch Capital Partners LLC NY reduced its stake in Humana Inc. (NYSE:HUM) by 1.1% during the 4th quarter, HoldingsChannel reports. The firm owned 34,935 shares of the insurance provider’s stock after selling 380 shares during the period. Humana accounts for 4.3% of Welch Capital Partners LLC NY’s portfolio, making the stock its 5th biggest position. Welch Capital Partners LLC NY’s holdings in Humana were worth $15,994,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Ameriprise Financial Inc. raised its stake in shares of Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after buying an additional 402,559 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Humana by 39.3% in the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after purchasing an additional 192,546 shares during the period. Quadrature Capital Ltd boosted its holdings in Humana by 814.5% during the third quarter. Quadrature Capital Ltd now owns 181,787 shares of the insurance provider’s stock worth $88,448,000 after buying an additional 161,909 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in Humana by 2,659.2% during the third quarter. Adage Capital Partners GP L.L.C. now owns 152,860 shares of the insurance provider’s stock worth $74,369,000 after buying an additional 147,320 shares during the period. Finally, International Assets Investment Management LLC increased its holdings in Humana by 32,648.4% in the fourth quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock valued at $61,619,000 after buying an additional 134,185 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HUM has been the topic of several research reports. Bank of America reissued a “neutral” rating and issued a $342.00 target price (down previously from $470.00) on shares of Humana in a report on Tuesday, April 2nd. Cantor Fitzgerald reduced their target price on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. UBS Group dropped their price target on Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, April 25th. Royal Bank of Canada decreased their price objective on Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Finally, Truist Financial reissued a “hold” rating and issued a $550.00 target price on shares of Humana in a research note on Friday, January 19th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average price target of $424.50.

Humana Stock Performance

Shares of NYSE HUM traded down $1.06 during midday trading on Tuesday, hitting $302.09. The company’s stock had a trading volume of 1,565,451 shares, compared to its average volume of 1,990,495. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The firm’s fifty day moving average price is $326.86 and its 200-day moving average price is $393.28. The firm has a market cap of $36.40 billion, a P/E ratio of 19.03, a P/E/G ratio of 1.79 and a beta of 0.45.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $9.38 earnings per share. On average, sell-side analysts forecast that Humana Inc. will post 16.08 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.